Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting
December 11, 2024 08:00 ET
|
Intra-Cellular Therapies, Inc.
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data...
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
December 03, 2024 07:30 ET
|
Intra-Cellular Therapies, Inc.
The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA’s robust antidepressant efficacy and favorable safety and tolerability profileCAPLYTA, if approved as an...
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
November 19, 2024 08:00 ET
|
Intra-Cellular Therapies, Inc.
BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for...
Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
November 07, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...
Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia
November 05, 2024 07:00 ET
|
Intra-Cellular Therapies Inc.
The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically...
Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance
October 30, 2024 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 2024...
Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast
October 17, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress
September 23, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster...
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences
August 28, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
August 08, 2024 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...